| Compugen Announces Leadership Transitions Effective September 2025 |
Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of Directors Eran Ophir, Ph.D. |
prnewswire.com |
2025-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025 |
HOLON, Israel , May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2025 financial results on Monday, May 19, 2025, before the U.S. financial markets open. |
prnewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Participate in Multiple Virtual Investor Conferences in April 2025 |
HOLON, Israel , March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025: H.C. |
prnewswire.com |
2025-03-26 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript |
Compugen Ltd. (NASDAQ:CGEN ) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Karina Rabayeva – Truist Securities Daina Graybosch - Leerink Partners Leland Gershell - Oppenheimer Tony Butler - Rodman and Renshaw Stephen Willey - Stifel Operator Ladies and gentlemen, thank you for joining us today. |
seekingalpha.com |
2025-03-04 12:34:33 |
Czytaj oryginał (ang.) |
| Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates |
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.07. This compares to earnings of $0.11 per share a year ago. |
zacks.com |
2025-03-04 11:15:32 |
Czytaj oryginał (ang.) |
| Compugen Reports Fourth Quarter and Full Year 2024 Results |
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025 The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to Gilead Partner AstraZeneca reported promising rilvegostomig data in 2024, expanded the rilvegostomig program to seven Phase 3 trials across lung and gastrointestinal cancers and plans to share early data for rilvegostomig in combination with their ADCs in 2025 Solid financial position with cash runway expected to fund operations into 2027 HOLON, Israel , March 4, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2024 and provided a corporate update. |
prnewswire.com |
2025-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference |
HOLON, ISRAEL , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, Miami Beach, Florida, on Tuesday, March 11, 2025 at 8:00 AM ET. |
prnewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology |
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology and immune regulation Leveraging Compugen's computational analytical tools uncovered high consistency in single-cell expression levels across Ultima's UG 100 sequencing platform, offering a potential advantage for demarcation of transcript termination. Research presented at Advances in Genome Biology and Technology (AGBT) 2025 General Meeting HOLON, Israel , Feb. 26, 2025 /PRNewswire/ -- Compugen Ltd. |
prnewswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025 |
HOLON, Israel , Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open. |
prnewswire.com |
2025-02-18 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen: Immuno-Oncology Innovator Poised For A Comeback |
Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in cash and milestone payments from Gilead and AstraZeneca, Compugen has a solid financial runway extending into 2027. Compugen's pipeline, including COM701 and COM503, aims to transform tumor responsiveness through unique immunotherapy strategies, potentially reshaping the immuno-oncology landscape. |
seekingalpha.com |
2025-02-18 08:11:44 |
Czytaj oryginał (ang.) |
| Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
HOLON, Israel , Feb. 4, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference which will take place virtually on February 11, 2025 at 8am ET. |
prnewswire.com |
2025-02-04 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen initiated with bullish view at Oppenheimer, here's why |
Compugen +0.05 (+3.14%) AstraZeneca +0.44 (+0.66%) Gilead +0.7 (+0.79%) |
https://thefly.com |
2025-01-13 09:57:41 |
Czytaj oryginał (ang.) |
| Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors |
New approach to harness cytokine biology to treat cancer patients advances to the clinic First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gilead Sciences, Inc. Phase 1 dose escalation and dose expansion trial to assess the safety and tolerability of COM503 as monotherapy and in combination for patients with advanced solid tumors Compugen responsible for running the Phase 1 trial HOLON, Israel , Jan. 8, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead. |
prnewswire.com |
2025-01-08 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies |
Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer Further strengthens Compugen's IP portfolio across DNAM-1 axis checkpoint inhibitors HOLON, Israel , Nov. 27, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company's potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer. |
prnewswire.com |
2024-11-27 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript |
Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN ) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program Yvonne Naughton - Head of IR and Corporate Communications Conference Call Participants Stephen Willey - Stifel Daina Graybosch - Leerink Partners Tony Butler - Rodman and Renshaw Asthika Goonewardene - Truist Securities Operator Ladies and gentlemen, thank you for joining us today. |
seekingalpha.com |
2024-11-12 17:35:24 |
Czytaj oryginał (ang.) |
| Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates |
Compugen (CGEN) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.11 per share a year ago. |
zacks.com |
2024-11-12 14:05:12 |
Czytaj oryginał (ang.) |
| Compugen Reports Third Quarter 2024 Results |
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the Company Plans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting, to evaluate single agent COM701 and future combinations representing an unmet need and regulatory and commercial opportunity On track to initiate Phase 1 trial evaluating COM503 (anti-IL18BP) in solid tumors in Q4 2024 Partner AstraZeneca reported encouraging rilvegostomig data at WCLC and ESMO 2024 and advanced rilvegostomig into two additional Phase 3 lung cancer trials Solid balance sheet with expected cash runway into 2027 anticipated to reach potential key catalysts, including projected COM701 sub-study 1 interim analysis and support advancement of COM503 in the clinic HOLON, Israel , Nov. 12, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update. |
prnewswire.com |
2024-11-12 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Participate in Stifel 2024 Healthcare Conference |
HOLON, Israel , Nov. 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen management will participate in a fireside chat at the upcoming Stifel 2024 Healthcare Conference in New York City. |
prnewswire.com |
2024-11-11 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 |
HOLON, ISRAEL , Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC). |
prnewswire.com |
2024-11-05 11:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 |
HOLON, Israel , Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, before the U.S. financial markets open. |
prnewswire.com |
2024-10-29 09:00:00 |
Czytaj oryginał (ang.) |
| Compugen Gears Up to Report Q3 Earnings: Here's What to Expect |
On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies. |
zacks.com |
2024-10-24 17:15:37 |
Czytaj oryginał (ang.) |
| Compugen to Present New Clinical Data at SITC 2024 |
HOLON, Israel , Oct. 7, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that new clinical data supporting the anti-tumor activity and safety of the triple combination COM701, COM902 and pembrolizumb in heavily pre-treated patients with platinum resistant ovarian cancer will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 8-10, 2024, in Houston, Texas. |
prnewswire.com |
2024-10-07 11:00:00 |
Czytaj oryginał (ang.) |
| Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock? |
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2024-09-11 17:00:37 |
Czytaj oryginał (ang.) |
| Compugen to Present at Single Cell Genomics 2024 Conference |
HOLON, Israel , Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd. |
prnewswire.com |
2024-09-09 11:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
HOLON, Israel , Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. |
prnewswire.com |
2024-08-29 11:00:00 |
Czytaj oryginał (ang.) |
| Can Compugen (CGEN) Run Higher on Rising Earnings Estimates? |
Compugen (CGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2024-08-26 17:20:24 |
Czytaj oryginał (ang.) |
| Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript |
Compugen Ltd. (NASDAQ:CGEN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today. |
seekingalpha.com |
2024-08-10 09:54:10 |
Czytaj oryginał (ang.) |
| Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates |
Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago. |
zacks.com |
2024-08-06 13:26:00 |
Czytaj oryginał (ang.) |
| Compugen Reports Second Quarter 2024 Results |
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024 Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the Company Solid balance sheet with cash runway expected to fund operations into 2027 HOLON, Israel , Aug. 6, 2024 /PRNewswire/ -- Compugen Ltd. |
prnewswire.com |
2024-08-06 11:00:00 |
Czytaj oryginał (ang.) |
| Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors |
FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer therapeutics as monotherapy and in combination in advanced solid tumors in Q4 2024 HOLON, Israel , July 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead Sciences, Inc. (Gilead). |
prnewswire.com |
2024-07-29 11:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 |
HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the U.S. financial markets open. |
prnewswire.com |
2024-07-23 11:00:00 |
Czytaj oryginał (ang.) |
| Compugen to Present at Upcoming Antibody Industrial Symposium |
HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France. |
prnewswire.com |
2024-06-17 11:00:00 |
Czytaj oryginał (ang.) |
| Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now |
After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
zacks.com |
2024-06-04 14:56:19 |
Czytaj oryginał (ang.) |